Hepatitis C Virus and Hepatocellular Carcinoma

  • Brett Lindenbach
Part of the Current Cancer Research book series (CUCR)


Hepatitis C virus (HCV) is strongly linked with the development of hepatocellular carcinoma. However, cancer arises in only a subset of patients, and takes several years to develop. Thus, the role of HCV in the etiology of cancer has remained elusive. I summarize here the clinical and molecular virological connections between HCV and liver cancer.


West Nile Virus Advanced Liver Fibrosis Interferon Monotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abid K, Pazienza V, de Gottardi A et al (2005) An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol 42(5):744–751PubMedCrossRefGoogle Scholar
  2. Ariumi Y, Kuroki M, Dansako H et al (2008) The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication. J Virol 82(19):9639–9646PubMedCrossRefGoogle Scholar
  3. Battaglia S, Benzoubir N, Nobilet S et al (2009) Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One 4(2):e4355PubMedCrossRefGoogle Scholar
  4. Bhatia SN, Balis UJ, Yarmush ML et al (1999) Effect of cell–cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J 13(14):1883–1900PubMedGoogle Scholar
  5. Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science (New York, NY) 290(5498):1972–1974CrossRefGoogle Scholar
  6. Blight KJ, McKeating JA, Rice CM (2002) Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76(24):13001–13014PubMedCrossRefGoogle Scholar
  7. Bruix J, Barrera JM, Calvet X et al (1989) Prevalence of antibodies to hepatitis C virus in spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2(8670):1004–1006PubMedCrossRefGoogle Scholar
  8. Bruno S, Silini E, Crosignani A et al (1997) Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology (Baltimore, MD) 25(3):754–758CrossRefGoogle Scholar
  9. Castells L, Vargas V, Gonzalez A et al (1995) Long interval between HCV infection and development of hepatocellular carcinoma. Liver 15(3):159–163PubMedGoogle Scholar
  10. Cheng PL, Chang MH, Chao CH et al (2004) Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-beta/Smad3-mediated transcriptional activation. Oncogene 23(47):7821–7838PubMedCrossRefGoogle Scholar
  11. Chiba T, Matsuzaki Y, Abei M et al (1996) Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 31(4):552–558PubMedCrossRefGoogle Scholar
  12. Choo Q-L, Kuo G, Weiner AJ et al (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (New York, NY) 244:359–362CrossRefGoogle Scholar
  13. Chou AH, Tsai HF, Wu YY et al (2005) Hepatitis C virus core protein modulates trail-mediated apoptosis by enhancing bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 174(4):2160–2166PubMedGoogle Scholar
  14. Colombo M, Kuo G, Choo QL et al (1989) Prevalence of antibodies to hepatitis C virus in italian patients with hepatocellular carcinoma. Lancet 2(8670):1006–1008PubMedCrossRefGoogle Scholar
  15. De Mitri MS, Poussin K, Baccarini P et al (1995) HCV-associated liver cancer without cirrhosis. Lancet 345(8947):413–415PubMedCrossRefGoogle Scholar
  16. Degos F, Christidis C, Ganne-Carrie N et al (2000) Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47(1):131–136PubMedCrossRefGoogle Scholar
  17. Deng L, Nagano-Fujii M, Tanaka M et al (2006) NS3 protein of hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol 87(Pt 6):1703–1713PubMedCrossRefGoogle Scholar
  18. Deuffic S, Poynard T, Valleron AJ (1999) Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat 6(5):411–413PubMedCrossRefGoogle Scholar
  19. Di Bisceglie AM, Shiffman ML, Everson GT et al (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359(23):2429–2441PubMedCrossRefGoogle Scholar
  20. Donato F, Tagger A, Chiesa R et al (1997) Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC study. Hepatology (Baltimore, MD) 26(3):579–584CrossRefGoogle Scholar
  21. Donato F, Boffetta P, Puoti M (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75(3):347–354PubMedCrossRefGoogle Scholar
  22. Donato F, Tagger A, Gelatti U et al (2002) Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155(4):323–331PubMedCrossRefGoogle Scholar
  23. Dustin LB, Rice CM (2007) Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 25:71–99PubMedCrossRefGoogle Scholar
  24. El-Serag HB (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology (Baltimore, MD) 36(5 Suppl 1):S74–S83CrossRefGoogle Scholar
  25. Freeman AJ, Dore GJ, Law MG et al (2001) Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (Baltimore, MD) 34(4 Pt 1):809–816CrossRefGoogle Scholar
  26. Gale M Jr, Kwieciszewski B, Dossett M et al (1999) Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 73(8):6506–6516PubMedGoogle Scholar
  27. Ghosh AK, Steele R, Meyer K et al (1999) Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 80(Pt 5):1179–1183PubMedGoogle Scholar
  28. Gong G, Waris G, Tanveer R et al (2001) Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 98(17):9599–9604PubMedCrossRefGoogle Scholar
  29. Gordon SC, Bayati N, Silverman AL (1998) Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology (Baltimore, MD) 28(2):562–567CrossRefGoogle Scholar
  30. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674PubMedCrossRefGoogle Scholar
  31. Honda A, Hatano M, Kohara M et al (2000a) HCV-core protein accelerates recovery from the insensitivity of liver cells to Fas-mediated apoptosis induced by an injection of anti-Fas antibody in mice. J Hepatol 33(3):440–447PubMedCrossRefGoogle Scholar
  32. Honda M, Kaneko S, Shimazaki T et al (2000b) Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology (Baltimore, MD) 31(6):1351–1359CrossRefGoogle Scholar
  33. Hoofnagle JH, di Bisceglie AM (1997) The treatment of chronic viral hepatitis. N Engl J Med 336(5):347–356PubMedCrossRefGoogle Scholar
  34. Ishido S, Fujita T, Hotta H (1998) Complex formation of NS5b with NS3 and NS4a proteins of hepatitis C virus. Biochem Biophys Res Commun 244(1):35–40PubMedCrossRefGoogle Scholar
  35. Jhaveri R, McHutchison J, Patel K et al (2008) Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis 197(2):283–291PubMedCrossRefGoogle Scholar
  36. Kamegaya Y, Hiasa Y, Zukerberg L et al (2005) Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology (Baltimore, MD) 41(3):660–667CrossRefGoogle Scholar
  37. Kao CF, Chen SY, Chen JY et al (2004) Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene 23(14):2472–2483PubMedCrossRefGoogle Scholar
  38. Kawamura T, Furusaka A, Koziel MJ et al (1997) Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology (Baltimore, MD) 25(4):1014–10121CrossRefGoogle Scholar
  39. Khetani SR, Bhatia SN (2008) Microscale culture of human liver cells for drug development. Nat Biotechnol 26(1):120–126PubMedCrossRefGoogle Scholar
  40. Kolykhalov AA, Agapov EV, Blight KJ et al (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (New York, NY) 277(5325):570–574CrossRefGoogle Scholar
  41. Korenaga M, Wang T, Li Y et al (2005) Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280(45):37481–37488PubMedCrossRefGoogle Scholar
  42. Kwun HJ, Jung EY, Ahn JY et al (2001) p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 82(Pt 9):2235–2241PubMedGoogle Scholar
  43. Lai CK, Jeng KS, Machida K et al (2008) Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology 370(2):295–309PubMedCrossRefGoogle Scholar
  44. Lan KH, Sheu ML, Hwang SJ et al (2002) HCV NS5a interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 21(31):4801–4811PubMedCrossRefGoogle Scholar
  45. Lanford RE, Chavez D, Chisari FV et al (1995) Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J Virol 69(12):8079–8083PubMedGoogle Scholar
  46. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29(Suppl 1):74–81PubMedCrossRefGoogle Scholar
  47. Lerat H, Honda M, Beard MR et al (2002) Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122(2):352–365PubMedCrossRefGoogle Scholar
  48. Li K, Prow T, Lemon SM et al (2002) Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells. Hepatology (Baltimore, MD) 35(5):1237–1246CrossRefGoogle Scholar
  49. Li K, Foy E, Ferreon JC et al (2005a) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 102(8):2992–2997PubMedCrossRefGoogle Scholar
  50. Li XD, Sun L, Seth RB et al (2005b) Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 102(49):17717–17722PubMedCrossRefGoogle Scholar
  51. Liang TJ, Heller T (2004) Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S62–S71PubMedCrossRefGoogle Scholar
  52. Liang TJ, Jeffers LJ, Reddy KR et al (1993) Viral pathogenesis of hepatocellular carcinoma in the united states. Hepatology (Baltimore, MD) 18(6):1326–1333Google Scholar
  53. Liang Y, Shilagard T, Xiao SY et al (2009) Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 137(4):1448–1458PubMedCrossRefGoogle Scholar
  54. Lindenbach BD, Evans MJ, Syder AJ et al (2005) Complete replication of hepatitis C virus in cell culture. Science (New York, NY) 309(5734):623–626CrossRefGoogle Scholar
  55. Lindenbach BD, Thiel HJ, Rice CM (2007) Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology, 1st edn. Lippincott-Raven Publishers, Philadelphia, pp 1101–1152Google Scholar
  56. Lohmann V, Korner F, Koch JO et al (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (New York, NY) 285:110–113CrossRefGoogle Scholar
  57. Lok AS, Seeff LB, Morgan TR et al (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136(1):138–148PubMedCrossRefGoogle Scholar
  58. Lu W, Lo SY, Chen M et al (1999) Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology 264(1):134–141PubMedCrossRefGoogle Scholar
  59. Machida K, Cheng KT, Sung VM et al (2004) Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 101(12):4262–4267PubMedCrossRefGoogle Scholar
  60. Machida K, Liu JC, McNamara G et al (2009) Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway. J Virol 83(23):12590–12600PubMedCrossRefGoogle Scholar
  61. Majumder M, Ghosh AK, Steele R et al (2001) Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 75(3):1401–1407PubMedCrossRefGoogle Scholar
  62. Majumder M, Steele R, Ghosh AK et al (2003) Expression of hepatitis C virus non-structural 5A protein in the liver of transgenic mice. FEBS Lett 555(3):528–532PubMedCrossRefGoogle Scholar
  63. Manns MP, McHutchison JG, Gordon SC et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958–965PubMedCrossRefGoogle Scholar
  64. Marukian S, Jones CT, Andrus L et al (2008) Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (Baltimore, MD) 48(6):1843–1850CrossRefGoogle Scholar
  65. Mazzella G, Accogli E, Sottili S et al (1996) Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24(2):141–147PubMedCrossRefGoogle Scholar
  66. McGivern DR, Lemon SM (2011) Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 30(17):1969–1983Google Scholar
  67. McGivern DR, Villanueva RA, Chinnaswamy S et al (2009) Impaired replication of hepatitis C virus containing mutations in a conserved NS5B retinoblastoma protein-binding motif. J Virol 83(15):7422–7433PubMedCrossRefGoogle Scholar
  68. Meylan E, Curran J, Hofmann K et al (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062):1167–1172PubMedCrossRefGoogle Scholar
  69. Milward A, Mankouri J, Harris M (2010) Hepatitis C virus NS5A protein interacts with beta-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion. J Gen Virol 91(Pt 2):373–381PubMedCrossRefGoogle Scholar
  70. Miyanari Y, Atsuzawa K, Usuda N et al (2007) The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9(9):1089–1097PubMedCrossRefGoogle Scholar
  71. Moradpour D, Englert C, Wakita T et al (1996) Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 222(1):51–63PubMedCrossRefGoogle Scholar
  72. Moriya K, Yotsuyanagi H, Shintani Y et al (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78(Pt 7):1527–1531PubMedGoogle Scholar
  73. Moriya K, Fujie H, Shintani Y et al (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065–1067PubMedCrossRefGoogle Scholar
  74. Munakata T, Nakamura M, Liang Y et al (2005) Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci USA 102(50):18159–18164PubMedCrossRefGoogle Scholar
  75. Munakata T, Liang Y, Kim S et al (2007) Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 3(9):1335–1347PubMedCrossRefGoogle Scholar
  76. Naas T, Ghorbani M, Alvarez-Maya I et al (2005) Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol 86(Pt 8):2185–2196PubMedCrossRefGoogle Scholar
  77. Nagao Y, Tanaka K, Kobayashi K et al (2004) A cohort study of chronic liver disease in an HCV hyperendemic area of Japan: a prospective analysis for 12 years. Int J Mol Med 13(2):257–265PubMedGoogle Scholar
  78. Nishiguchi S, Kuroki T, Nakatani S et al (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346(8982):1051–1055PubMedCrossRefGoogle Scholar
  79. Nomura-Takigawa Y, Nagano-Fujii M, Deng L et al (2006) Non-structural protein 4A of hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis. J Gen Virol 87(Pt 7):1935–1945PubMedCrossRefGoogle Scholar
  80. Okuda M, Li K, Beard MR et al (2002) Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122(2):366–375PubMedCrossRefGoogle Scholar
  81. Otsuka M, Kato N, Lan K et al (2000) Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem 275(44):34122–34130PubMedCrossRefGoogle Scholar
  82. Park CY, Choi SH, Kang SM et al (2009) Nonstructural 5a protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J Hepatol 51(5):853–864PubMedCrossRefGoogle Scholar
  83. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRefGoogle Scholar
  84. Pasquinelli C, Shoenberger JM, Chung J et al (1997) Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology (Baltimore, MD) 25(3):719–727CrossRefGoogle Scholar
  85. Pavio N, Battaglia S, Boucreux D et al (2005) Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway. Oncogene 24(40):6119–6132PubMedCrossRefGoogle Scholar
  86. Pereira AA, Jacobson IM (2009) New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol 6(7):403–411PubMedCrossRefGoogle Scholar
  87. Pietschmann T, Lohmann V, Kaul A et al (2002) Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 76(8):4008–4021PubMedCrossRefGoogle Scholar
  88. Pietschmann T, Kaul A, Koutsoudakis G et al (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 103(19):7408–7413PubMedCrossRefGoogle Scholar
  89. Pietschmann T, Zayas M, Meuleman P et al (2009) Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog 5(6):e1000475PubMedCrossRefGoogle Scholar
  90. Ploss A, Khetani SR, Jones CT et al (2010) Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci USA 107(7):3141–3145PubMedCrossRefGoogle Scholar
  91. Podevin P, Carpentier A, Pene V et al (2010) Production of infectious hepatitis c virus in primary cultures of human adult hepatocytes. Gastroenterology 139(4):1355–1364Google Scholar
  92. Prikhod’ko EA, Prikhod’ko GG, Siegel RM et al (2004) The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities. Virology 329(1):53–67PubMedCrossRefGoogle Scholar
  93. Qadri I, Iwahashi M, Simon F (2002) Hepatitis C virus NS5A protein binds TBP and p53, inhibiting their DNA binding and p53 interactions with TBP and ERCC3. Biochim Biophys Acta 1592(2):193–204PubMedGoogle Scholar
  94. Ray RB, Steele R, Meyer K et al (1998) Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene 208(2):331–336PubMedCrossRefGoogle Scholar
  95. Resnick RH, Koff R (1993) Hepatitis C-related hepatocellular carcinoma. Prevalence and significance. Arch Intern Med 153(14):1672–1677PubMedCrossRefGoogle Scholar
  96. Sacco R, Tsutsumi T, Suzuki R et al (2003) Antiapoptotic regulation by hepatitis C virus core protein through up-regulation of inhibitor of caspase-activated DNase. Virology 317(1):24–35PubMedCrossRefGoogle Scholar
  97. Serfaty L, Aumaitre H, Chazouilleres O et al (1998) Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (Baltimore, MD) 27(5):1435–1440CrossRefGoogle Scholar
  98. Siavoshian S, Abraham JD, Kieny MP et al (2004) HCV core, NS3, NS5A and NS5B proteins modulate cell proliferation independently from p53 expression in hepatocarcinoma cell lines. Arch Virol 149(2):323–336PubMedCrossRefGoogle Scholar
  99. Steinkühler C (2004) Hepacivirin. In: Barrett AJ, Rawlings ND, Woessner JF (eds) Handbook of proteolytic enzymes, 2nd edn. Elsevier, London, pp 1773–1779Google Scholar
  100. Street A, Macdonald A, Crowder K et al (2004) The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 279(13):12232–12241PubMedCrossRefGoogle Scholar
  101. Street A, Macdonald A, McCormick C et al (2005) Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. J Virol 79(8):5006–5016PubMedCrossRefGoogle Scholar
  102. Sung VM, Shimodaira S, Doughty AL et al (2003) Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 77(3):2134–2146PubMedCrossRefGoogle Scholar
  103. Tanaka Y, Hanada K, Mizokami M et al (2002) A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 99(24):15584–15589PubMedCrossRefGoogle Scholar
  104. Tanaka M, Nagano-Fujii M, Deng L et al (2006) Single-point mutations of hepatitis C virus NS3 that impair p53 interaction and anti-apoptotic activity of NS3. Biochem Biophys Res Commun 340(3):792–799PubMedCrossRefGoogle Scholar
  105. Tong MJ, el-Farra NS, Reikes AR et al (1995) Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332(22):1463–1466PubMedCrossRefGoogle Scholar
  106. Umemura T, Ichijo T, Yoshizawa K et al (2009) Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 44(Suppl 19):102–107PubMedCrossRefGoogle Scholar
  107. Valla DC, Chevallier M, Marcellin P et al (1999) Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology (Baltimore, MD) 29(6):1870–1875CrossRefGoogle Scholar
  108. Wakita T, Pietschmann T, Kato T et al (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11(7):791–796PubMedCrossRefGoogle Scholar
  109. Wang AG, Lee DS, Moon HB et al (2009) Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J Pathol 219(2):253–262PubMedCrossRefGoogle Scholar
  110. Yanagi M, Purcell RH, Emerson SU et al (1997) Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 94(16):8738–8743PubMedCrossRefGoogle Scholar
  111. Yi M, Villanueva RA, Thomas DL et al (2006) Production of infectious genotype 1a hepatitis C virus (hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA 103(7):2310–2315PubMedCrossRefGoogle Scholar
  112. Yoshizawa H (2002) Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 62(Suppl 1):8–17PubMedCrossRefGoogle Scholar
  113. Zhong J, Gastaminza P, Cheng G et al (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102(26):9294–9299PubMedCrossRefGoogle Scholar
  114. Zhu N, Khoshnan A, Schneider R et al (1998) Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 72(5):3691–3697PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Section of Microbial PathogenesisYale University School of Medicine, 354C Boyer Center for Molecular MedicineNew HavenUSA

Personalised recommendations